Ask about this productRelated genes to: ICAM1 antibody
- Gene:
- ICAM1 NIH gene
- Name:
- intercellular adhesion molecule 1
- Previous symbol:
- -
- Synonyms:
- BB2, CD54
- Chromosome:
- 19p13.2
- Locus Type:
- gene with protein product
- Date approved:
- 1989-04-24
- Date modifiied:
- 2016-01-15
Related products to: ICAM1 antibody
Related articles to: ICAM1 antibody
- Benzo[a]pyrene (BaP), a ubiquitous environmental pollutant, exerts hepatotoxicity primarily through its metabolite BPDE. This study combined network toxicology and experimental validation to delineate the mechanisms of BaP-induced liver injury and fibrosis. Network analysis identified ICAM-1 as a potential core target, and previous clinical data confirmed its upregulation in liver injury patients. In a rat model, BaP exposure induced dose-dependent hepatic injury and oxidative stress. Mechanistically, BaP activated the NF-κB/TNF-α signaling axis, upregulating ICAM-1 and initiating NLRP3 inflammasome assembly. Activated NLRP3 promoted Caspase-1-dependent cleavage of GSDMD, leading to hepatocyte pyroptosis and the release of IL-1β and IL-18. Concurrently, ICAM-1 facilitated inflammatory cell infiltration. This sustained inflammatory microenvironment ultimately activated the TGF-β/α-SMA/Col-I axis, driving hepatic stellate cell activation and excessive extracellular matrix deposition, thereby promoting liver fibrosis. Our findings elucidate a cascading pathway linking BaP exposure to oxidative stress, NLRP3-mediated pyroptosis, and hepatic fibrogenesis. - Source: PubMed
Publication date: 2026/09/26
Wang BoheDong XiuxiaLi JiayueFeng XiaojuanChen YongkangLiu NaFu PengjuanWang JunlingLi Xiangli - Constipation affects approximately 20% of the US population, with diverse treatment options available due to the unclear onset and causes of the condition. Recently, focused ultrasound (FUS) has been proposed as a novel, non-invasive peripheral neuromodulatory treatment that may reduce this inflammation. We utilized a loperamide-induced constipation rat model, which is a widely used model to study constipation and potential therapeutic interventions. This study investigated the effects of FUS treatment on colonic inflammation and motility. We report that loperamide treatment did not alter colon morphology, but upregulated interleukin (IL)-6, IL-10, IL-1ra and several other cytokines. FUS treatment notably reduced the expression of IL-2, IL-4, IL-17 and other markers of inflammation. Additionally, FUS therapy also reduced the expression of chemokines, such as CXC3CL-1 and CXCL-7, and acute phase proteins, including vascular endothelial growth factor and intercellular adhesion molecule 1 in loperamide-FUS-treated rats. One week post-treatment, cytokine and chemokine profiles showed a sustained decrease of inflammation in the distal colon, with FUS treatment continuing to reduce several inflammatory mediators. These results demonstrate non-invasive FUS markedly reduced the expression of pro-inflammatory cytokines, chemokines and acute phase proteins in both the proximal and distal colon of loperamide-treated rats and can plausibly serve as a therapeutic for chronic constipation and other inflammatory gastrointestinal disorders. - Source: PubMed
Publication date: 2026/09/26
Shah DiaAkhtar KainatDwivedi DevSiddiqui AmalHaggas GriffinForman NicoleGervase TatianaKao YifanChen JohnBrzac JuliaMolho EricShin Damian - Covalent conjugation of ligand molecules to force sensors provides a powerful approach to image receptor-transmitted cellular forces. While this strategy is effective for small-molecule ligands, the conjugation process can damage large protein ligands. To address this challenge, we developed a modular mechano-fluorescent coating (mMFC) that enables receptor-specific force imaging using widely available biotinylated ligands. The mMFC construct consists of a poly-L-lysine (PLL) backbone for substrate adsorption, polyethylene glycol (PEG) grafts to prevent nonspecific binding, and DNA-based integrative tension sensors (ITS) as force-reporting units. Benefiting from copper-free click chemistry, the mMFC is synthesized via a simple one-pot reaction. During application, the mMFC is adsorbed onto substrates, and biotinylated ligands are subsequently linked to the mMFC construct via biotin-avidin interactions, where the ITS reports receptor-transmitted forces by fluorescence. By testing HeLa cells, platelets, and human T lymphocytes on mMFC platforms, we imaged cellular forces transmitted through RGD peptide, latency-associated peptide (LAP), ICAM-1, and anti-CD3, which target integrins, LFA-1, and T cell receptor (TCR) complex, respectively. We further demonstrated molecular force calibration and single-molecule force imaging of these receptors using the mMFC platform. Overall, the mMFC provides a modular, convenient, and robust platform for investigating mechanotransduction across diverse receptors in various cell types. - Source: PubMed
Publication date: 2026/09/26
Pandey VivekTu YingIkegami SachieWang Sarah JZhan YingWang Xuefeng - [This corrects the article DOI: 10.3389/fimmu.2026.1864741.]. - Source: PubMed
Publication date: 2026/09/11
Zettl InesEllinger IsabellaZghaebi MohammedJance SarahIzewski VanessaDrescher AnjaBreiteneder HeimoRöck ManuelTollinger MartinEckl-Dorna JuliaTillib Sergei VFlicker Sabine - This study investigated potential plasma biomarkers associated with cancer risk and mortality in patients with type 2 diabetes mellitus (T2DM), a population known to have an increased cancer incidence and poorer outcomes compared with non-diabetic individuals. Traditional metabolic indicators, including blood pressure, blood glucose and blood lipids, have limited predictive value for cancer risk, highlighting the need for novel clinical biomarkers. In total, 141 subjects with T2DM were enrolled in this study. Plasma inflammatory and lipid-related biomarkers included cluster of differentiation 147 (CD147), cyclophilin A (CyPA), cytokines, oxidized low-density lipoprotein (oxi-LDL), oxi-LDL antibody and proprotein convertase subtilisin/kexin type 9 (PCSK9). Among all participants, 37.6% were obese (body mass index ≥27 kg/m). During 10 years of follow-up, all-cause mortality reached 35% and cancer incidence was 16%. Obese diabetic patients exhibit elevated oxi-LDL, soluble intercellular adhesion molecule-1, PCSK9, CD147 and CyPA levels. Deceased patients had a higher incidence of cancer and significantly lower plasma CD147 levels than surviving patients. Receiver operating characteristic curve analysis identified PCSK9 as a potential predictor of cancer occurrence in obese individuals with T2DM [area under the curve (AUC)=0.726], whereas CD147 showed modest predictive value in non-obese patients with diabetes (AUC=0.665). These findings suggest that plasma PCSK9 and CD147 may be associated with cancer occurrence in specific subgroups of patients with T2DM. However, larger prospective studies are required to confirm these associations and to further evaluate their potential value in cancer risk assessment. - Source: PubMed
Publication date: 2026/09/11
Tsao Lien-ChengKuo Chen-LingCheng Yu-ShanHuang Ching-ShanLiu Chin-SanSu Shih-Li